SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Ш

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre	ss of Reporting Person	n*	2. Issuer Name and Ticker or Trading Symbol Lexaria Bioscience Corp. [LEXX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) 100 - 740 MCC	(First) (Middle) URDY ROAD		3. Date of Earliest Transaction (Month/Day/Year) 10/14/2022	X Officer (give title Other (specify below) Chief Financial Officer						
(Street) KELOWNA (City)	KELOWNA A1 V1X 2P7		 4. If Amendment, Date of Original Filed (Month/Day/Year) 	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)
common shares								1,833	D	
common shares	10/14/2022		A		121	Α	\$2.09	1,954	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(3), (3), (3), (3), (3), (3), (3), (3),															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options	\$5.04							04/15/2021	04/15/2026	Common Shares	4,000		4,000	D	
Stock Options	\$5.04							04/15/2022	04/15/2026	Common Shares	4,000		8,000	D	
Stock Options	\$5.04							04/15/2023	04/15/2026	Common Shares	4,000		12,000	D	
Stock Options	\$5.31							04/26/2022	04/26/2026	Common Shares	5,000		17,000	D	
Stock Options	\$7.08							06/08/2021	06/08/2026	Common Shares	8,000		25,000	D	
Stock Options	\$6.23							09/01/2021	09/01/2026	Common Shares	10,000		35,000	D	
Stock Options	\$2.91							08/29/2022	08/29/2027	Common Shares	11,000		46,000	D	

Explanation of Responses:

/Gregory Downey/

** Signature of Reporting Person

10/18/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5